RecruitingNot Applicable

Asian Myeloproliferative Neoplasm (MPN) Registry

Hong Kong1,000 participantsStarted 2023-05

Plain-language summary

This is a multinational, multicenter, prospective and retrospective, observational, cohort study of patients with myeloproliferative neoplasm.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Age ≥ 18 years old at the time of diagnosis of MPN.
. Subject was diagnosed with one of the following disorders according to the 2017 WHO classification (for patients diagnosed before 2017, the bone marrow reports will be re-evaluated according to the 2017 WHO classification):
. Polycythaemia vera
. Essential thrombocythemia
. Primary myelofibrosis, pre-fibrotic/early stage
. Primary myelofibrosis, overt fibrotic stage
. Post-polycythaemia vera myelofibrosis
. Post-essential thrombocythaemia myelofibrosis

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Time to progression to secondary myelofibrosis (for PV and ET)

Timeframe: 10 years

Progression-free survival (PFS)

Timeframe: 10 years

Overall survival (OS)

Timeframe: 10 years

Trial details

NCT IDNCT05882773

SponsorThe University of Hong Kong

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-05

Contact for this trial

Harinder Gill, MD

+852 22554542 gillhsh@hku.hk

View on ClinicalTrials.gov More Myeloproliferative Neoplasm trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Age ≥ 18 years old at the time of diagnosis of MPN.
. Subject was diagnosed with one of the following disorders according to the 2017 WHO classification (for patients diagnosed before 2017, the bone marrow reports will be re-evaluated according to the 2017 WHO classification):
. Polycythaemia vera
. Essential thrombocythemia
. Primary myelofibrosis, pre-fibrotic/early stage
. Primary myelofibrosis, overt fibrotic stage
. Post-polycythaemia vera myelofibrosis
. Post-essential thrombocythaemia myelofibrosis